BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BC Innovations | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...
BC Week In Review | Apr 13, 2018
Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on April 6, before...
BC Extra | Apr 9, 2018
Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on Friday, before the...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
BC Innovations | Feb 9, 2017
Translation in Brief

Delivering audio

Partially sheltered from the immune system and with enclosed fluids, the ear makes a good target for gene therapy, but the bulk of the relevant cells in the inner ear are notoriously difficult to transduce...
BC Week In Review | Jan 27, 2017
Company News

GenVec, Intrexon deal

Intrexon will acquire GenVec in a stock deal. GenVec shareholders will receive 0.297 Intrexon shares per GenVec share, or $6.56 per GenVec share based on Intrexon's close of $22.09 on Jan. 23, before the deal...
BC Week In Review | May 9, 2016
Clinical News

CGF166: Phase I/II restarted

According the GenVec, Novartis notified the biotech that a DSMB recommended continuation of an open-label, U.S. Phase I/II trial of CGF166 based on the DSMB’s review of safety and efficacy data from the 9 enrolled...
BC Extra | May 3, 2016
Clinical News

Hearing loss trial of GenVec gene therapy clears hurdle

GenVec Inc. (NASDAQ:GNVC) rose $0.02 to $0.80 on Monday after partner Novartis AG (NYSE:NVS; SIX:NOVN) told the biotech a DSMB recommended continuing a Phase I/II of gene therapy CGF166 to treat hearing loss. On Jan....
BioCentury | Apr 4, 2016
Finance

1Q approvals

1Q approvals Company Approval Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Japan approves Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D) Amgen Inc. (NASDAQ:AMGN) Japan approves Repatha evolocumab to treat familial hypercholesterolemia or hypercholesterolemia in patients...
Items per page:
1 - 10 of 20